Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer

Justin A. Harold; Stephanie C. Free; William H. Bradley

Gynecologic Oncology Reports (Nov 2018)

Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer

Justin A. Harold,
Stephanie C. Free,
William H. Bradley

Affiliations

Justin A. Harold: Department of Obstetrics and Gynecology, Medical College of Wisconsin, United States
Stephanie C. Free: Department of Pharmacy, Froedtert Hospital, United States
William H. Bradley: Department of Obstetrics and Gynecology, Medical College of Wisconsin, United States; Corresponding author at: Medical College of Wisconsin and Froedtert Hospital, Department of Obstetrics and Gynecology, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, United States.

Journal volume & issue: Vol. 26
pp. 91 – 93

Abstract

Read online

A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialysis and a clinically significant disease response was appreciated.

Published in Gynecologic Oncology Reports

ISSN: 2352-5789 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Gynecology and obstetrics; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/gynecologic-oncology-reports/

About the journal